EPZICOM
LOE ApproachingNDAORALTABLET
Approved
Aug 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
EPZICOM by GSK is mechanism of action: abacavir is a carbocyclic synthetic nucleoside analogue. Approved for hiv-1 infection. First approved in 2004.
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPZICOM is a fixed-dose combination tablet containing abacavir and lamivudine, two nucleoside reverse transcriptase inhibitors (NRTIs) used to treat HIV-1 infection. Both active ingredients work by inhibiting HIV reverse transcriptase and terminating viral DNA chain elongation. The drug is administered orally as part of combination antiretroviral therapy.
$0.677MPart D
LOE ApproachingDeclining
As loss of exclusivity approaches, EPZICOM brand team is transitioning to defensive strategy with reduced headcount and focus on patient retention initiatives.
Mechanism of Action
Mechanism of Action: Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted by cellular enzymes to the active metabolite, carbovir triphosphate (CBV-TP), an analogue of deoxyguanosine-5′-triphosphate (dGTP). CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT)…
Indications (1)
Worked on EPZICOM at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.